106973-37-9

Usage

Uses

Used in Pharmaceutical Industry:
(3S)-4-Benzyl-5-oxomorpholine-3-carboxylic acid is utilized as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block for the development of new drugs with potential therapeutic applications.
Used in Chemical Synthesis:
In the field of organic chemistry, (3S)-4-Benzyl-5-oxomorpholine-3-carboxylic acid serves as a key intermediate for the synthesis of a wide range of organic compounds. Its versatile structure allows for further functionalization and modification, enabling the creation of novel molecules with diverse properties and applications.
Used in Research and Development:
(3S)-4-Benzyl-5-oxomorpholine-3-carboxylic acid is employed as a research tool in academic and industrial laboratories. Its unique structure and properties make it an interesting subject for studies in organic synthesis, medicinal chemistry, and materials science. Researchers can use (3S)-4-Benzyl-5-oxomorpholine-3-carboxylic acid to explore new reaction pathways, investigate its biological activity, or develop new methods for its synthesis and modification.

Upstream product

• 100-52-7 benzaldehyde 
• 56-45-1 L-serin 
• 79-04-9 chloroacetyl chloride 
• 515156-88-4 N-benzyl-D-serine 
• 106910-76-3 (S)-2-(benzylamino)-3-hydroxypropanoic acid 

Downstream Products

• 101376-26-5 (3R)-4-benzyl-3-(hydroxymethyl)-morpholine 
• 385802-30-2 (3S)-5-oxo-N,4-bis(phenylmethyl)-3-morpholinecarboxamide 
• 714971-27-4 (R)-(4-benzylmorpholin-3-yl)methanol hydrochloride 
• 1152111-36-8 (3S)-N,N-dimethyl-5-oxo-4-phenylmethyl-3-morpholinecarboxamide 
• 1126432-05-0 (9aR)-8-(phenylmethyl)octahydropyrazino[2,1-c][1,4]oxazine 
• 1126432-04-9 (9aR)-octahydropyrazino[2,1-c][1,4]oxazine dihydrochloride 
• 169750-73-6 (3R)-[4-benzylmorpholin-3-yl]methanamine 
• 215917-99-0 (R)-3-(hydroxymethyl)morpholine-4-carboxylic acid tert-butyl ester 
• 714971-09-2 [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid (3S)-3-morpholinylmethyl ester 
• 714971-12-7 (S)-tert-butyl 3-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-ylcarbamoyloxy)methyl)morpholine-4-carboxylate 
• 211053-49-5 (R)-3-hydroxymethylmorpholine 
• 917572-28-2 (S)-4-benzyl-3-(chloromethyl)morpholine 
• 681851-33-2 2,2,2-trichloro (S)-3-{[(phenylmethyl)sulfanyl]methyl}morpholine-4-carboxylate 
• 681851-31-0 (S)-4-(phenylmethyl)-3-{[(phenylmethyl)sulfanyl]methyl}morpholine 

Relevant academic research and scientific papers

A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor

The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure-activity relationship (SAR) studies led to the identification of compound 12b with a ～450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.

PEPTIDE DEFORMYLASE INHIBITORS

The present invention relates to {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3- oxopropyl}hydroxyformamide compounds of Formula (I): or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity and in treatment methods for bacterial infections

N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurolo

Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H- indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epide

Structure-activity relationships in a series of 4-[1H-indazol-5-ylamino] pyrrolo[2,1-f][1,2,4]triazine-6-carbamates identified dual human epidermal growth factor receptor (HER)1/HER2 kinase inhibitors with excellent biochemical potency and kinase selectiv

SYNTHETIC PROCESS

The present invention provides a process for preparing compounds of formula (I) ["insert chemical structure here"](I)or a pharmaceutically acceptable salt thereof. The compounds prepared by the process of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

Properties and Reactions of Substituted 1,2-Thiazetidine 1,1-Dioxides: Chiral Mono- and Bicyclic 1,2-Thiazetidine 1,1-Dioxides from α-Amino Acids

New chiral mono- and bicyclic β-sultams, valuable building blocks for drug synthesis, have been prepared from L-Ala, L-Val, L-Leu, L-Ile, L-Phe, L-Cys, L-Ser, L-Thr, and D-penicillamine by transformation of the COOH group into a methylsulfonyl chloride function, followed by cyclization under basic conditions. Selected properties, derivatives, and reactions of the β-sultams are described.

Chiral Synthesis of 3-Substituted Morpholines via Serine Enantiomers and Reductions of 5-Oxomorpholine-3-carboxylates

The chiral synthesis of 3-hydroxymethyl- and 3-carboxy-morpholines from serine enantiomers is described.Chemoselective and total reductions of 5-oxomorpholine-3-carboxylates are key synthetic steps.